Sherry Shen, MD
@sherryshenmd.bsky.social
Breast med onc & researcher at MSKCC, Co-Director of the MSK Lobular Breast Cancer Program, Columbia Med & UMich alum
When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!
December 13, 2024 at 2:09 PM
When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!
First Bluesky post! EMBER-3 presented by my mentor @breastcancerdoc.bsky.social demonstrating greater mPFS as single agent vs. SOC ET in ESR1mut, and impressive benefit of imlunestrant+abema with mPFS 9.4 months, 59% had prior CDK4/6i. Novel ET + CDK4/6i switch is intriguing - ELAINE3 is enrolling!
December 11, 2024 at 4:21 PM
First Bluesky post! EMBER-3 presented by my mentor @breastcancerdoc.bsky.social demonstrating greater mPFS as single agent vs. SOC ET in ESR1mut, and impressive benefit of imlunestrant+abema with mPFS 9.4 months, 59% had prior CDK4/6i. Novel ET + CDK4/6i switch is intriguing - ELAINE3 is enrolling!